Novo Nordisk A/S (NYSE:NVO) Stock Position Lowered by Transamerica Financial Advisors Inc.

Transamerica Financial Advisors Inc. lessened its position in Novo Nordisk A/S (NYSE:NVO) by 47.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 897 shares of the company’s stock after selling 824 shares during the quarter. Transamerica Financial Advisors Inc.’s holdings in Novo Nordisk A/S were worth $107,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Finally, Halpern Financial Inc. lifted its position in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $106.12 on Thursday. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The firm’s fifty day simple moving average is $113.80 and its 200 day simple moving average is $128.33. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $476.22 billion, a PE ratio of 34.34, a PEG ratio of 1.35 and a beta of 0.42.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on NVO shares. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.